

Special Issue

Immune Response and Vaccines for SARS-CoV-2 Infection

Message from the Guest Editor

With the recent COVID-19 pandemic, much research has been conducted on this topic "Immune Response and Vaccines for SARS-CoV-2 Infection". While mRNA has been studied since the 1990s, in recent years, mRNA has generated significant excitement for human use despite the licensure of several veterinary DNA vaccines. Recently, Pfizer and Moderna launched an mRNA vaccine for SARS-CoV-2, which has been administered to people across the globe. DNA and RNA vaccines are faster and cheaper to produce in large quantities than conventional vaccines. On the other hand, conventional vaccines often use "weakened" or "killed" versions of a virus, meaning that laboratories need to produce huge amounts of the virus. They often also include a protein, which is needed to spark a human immune response. However, producing a virus and a viral protein can be time-intensive and expensive. Therefore, this Special Issue will serve as a forum where scientists can share their latest research findings on the immune responses and vaccines related to infectious diseases, particularly SARS-CoV-2.

Guest Editor

Dr. Shumaila Hanif

Department of Biomedical Sciences, University of Pikeville, Coal Building, Office 718, 147 Sycamore Street, Pikeville, KY 41501, USA

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/139485

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).